Core Viewpoint - The company, Yinnuo Pharmaceutical-B, has seen a significant stock price increase following the announcement of its clinical trial application for a new veterinary drug aimed at treating diabetes in pets, indicating strong market interest and potential growth in the pet pharmaceutical sector [1] Group 1: Company Developments - Yinnuo Pharmaceutical-B's core product, Isupatide α, has had its clinical trial application for treating pet diabetes officially accepted by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The company plans to commence Phase I clinical trials in the first quarter of 2026, reflecting a strategic move into the pet pharmaceutical market [1] - The board believes that developing diabetes medication for pets has significant prospects, as pet owners are increasingly willing to invest in extending their pets' lifespans [1] Group 2: Regulatory Compliance and Research Progress - The company has adhered to all regulatory standards and requirements related to veterinary drug research and registration set by the Ministry of Agriculture [1] - Yinnuo Pharmaceutical-B has successfully completed relevant preclinical trials, showing positive results in efficacy and safety for Isupatide α in managing pet diabetes [1] - The positive outcomes from preclinical trials provide a solid basis for the subsequent clinical trials and registration applications for the drug [1]
银诺医药-B早盘拉升逾17% 依苏帕格鲁肽α在宠物糖尿病管理已取得积极进展